Vanguard Capital Management’s Heron Therapeutics HRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding HRTX
Vanguard Capital Management's HRTX Position: Q3 2026 in Review
Vanguard Capital Management increased its Heron Therapeutics (HRTX) stake by 0.48% in Q3 2026, buying an estimated $14.2K and bringing the position to 7,820,161 shares worth $2.46M. The position accounts for ﹤0.01% of the portfolio, ranked #3316.
Vanguard Capital Management first reported a position in HRTX in Q1 2026 and has held it in 3 quarters since. The position peaked at $6.25M in Q1 2026. 159 funds tracked by Wall St. Rank hold HRTX as of Q3 2026.
- Vanguard Capital Management held 7,820,161 shares of Heron Therapeutics worth $2.46M as of Q3 2026.
- Vanguard Capital Management bought 37,420 Heron Therapeutics shares in Q3 2026, an estimated $14.2K.
- Heron Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3316 holding.
- Vanguard Capital Management first reported a position in Heron Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Heron Therapeutics position peaked at $6.25M in Q1 2026.
- 159 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.